# Safety and Efficacy Evaluation of LC-K76 in Patients With Metastatic Hormone-Sensitive Prostate Cancer

> **NCT07389174** · EARLY_PHASE1 · NOT_YET_RECRUITING · sponsor: **Shanghai Changzheng Hospital** · enrollment: 40 (estimated)

## Conditions studied

- mHSPC
- mHNPC
- Prostate Cancer Adenocarcinoma

## Interventions

- **DRUG:** Standard Endocrine Therapy
- **DIETARY_SUPPLEMENT:** LC-K76

## Key facts

- **NCT ID:** NCT07389174
- **Lead sponsor:** Shanghai Changzheng Hospital
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-02
- **Primary completion:** 2027-01
- **Final completion:** 2027-06
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2026-02-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07389174

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07389174, "Safety and Efficacy Evaluation of LC-K76 in Patients With Metastatic Hormone-Sensitive Prostate Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07389174. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*